State Street’s Trevi Therapeutics TRVI Stock Holding History

State Street’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$56.5M	Buy	3,027,315 +362,002	+14%	+$5.26M	﹤0.01%	1771
2026 Q1	$31.8M	Buy	2,665,313 +230,313	+9%	+$2.58M	﹤0.01%	1979
2025 Q4	$30.5M	Buy	2,435,000 +215,578	+10%	+$2.49M	﹤0.01%	2019
2025 Q3	$20.3M	Buy	2,219,422 +386,502	+21%	+$2.9M	﹤0.01%	2234
2025 Q2	$10M	Buy	1,832,920 +408,414	+29%	+$2.54M	﹤0.01%	2603
2025 Q1	$8.96M	Buy	1,424,506 +253,824	+22%	+$1.21M	﹤0.01%	2595
2024 Q4	$4.82M	Buy	1,170,682 +217,770	+23%	+$697K	﹤0.01%	2999
2024 Q3	$3.18M	Buy	952,912 +53,051	+6%	+$158K	﹤0.01%	3157
2024 Q2	$2.68M	Buy	899,861 +101,612	+13%	+$282K	﹤0.01%	3198
2024 Q1	$2.75M	Buy	798,249 +57,056	+8%	+$127K	﹤0.01%	3171
2023 Q4	$993K	Buy	741,193 +32,600	+5%	+$49.4K	﹤0.01%	3482
2023 Q3	$1.54M	Buy	708,593 +28,000	+4%	+$63.3K	﹤0.01%	3422
2023 Q2	$1.63M	Buy	680,593 +581,051	+584%	+$1.46M	﹤0.01%	3476
2023 Q1	$184K	Hold	99,542	–	–	﹤0.01%	4104
2022 Q4	$192K	Buy	99,542 +22,500	+29%	+$44.3K	﹤0.01%	4115
2022 Q3	$119K	Buy	77,042 +37,200	+93%	+$122K	﹤0.01%	4394
2022 Q2	$112K	Buy	39,842 +3,000	+8%	+$7.37K	﹤0.01%	4477
2022 Q1	$81K	Buy	+36,842	New	+$38.2K	﹤0.01%	4700

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

State Street's TRVI Position: Q2 2026 in Review

State Street increased its Trevi Therapeutics (TRVI) stake by 14% in Q2 2026, buying an estimated $5.26M and bringing the position to 3,027,315 shares worth $56.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1771.

State Street first reported a position in TRVI in Q1 2022 and has held it in 18 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

State Street held 3,027,315 shares of Trevi Therapeutics worth $56.5M as of Q2 2026.
State Street bought 362,002 Trevi Therapeutics shares in Q2 2026, an estimated $5.26M.
Trevi Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1771 holding.
State Street first reported a position in Trevi Therapeutics in Q1 2022 and has held it in 18 quarters since.
219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.